medigraphic.com

2020, Number 3

<< Back Next >>

Rev Hematol Mex 2020; 21 (3)

Maintenance with lenalidomide following autologous hematopoietic stem cell transplantation in Mexican patients with multiple myeloma

Fernández-Vargas OE, Ron-Magaña AL, Barrera-Chairez E, Corona-Gutiérrez AA, Bañuelos-Ávila AJ

Language: Spanish
References: 33
Page: 129-135
PDF size: 277.87 Kb.


ABSTRACT

Background: In patients with multiple myeloma, maintenance treatment with lenalidomide following autologous hematopoietic stem cell transplantation (HSCT) prolongs both progression-free and overall survival and is now established as the standard of care.
Objective: To determine the effect of lenalidomide as maintenance therapy following autologous hematopoietic stem cell transplantation in Mexican patients with multiple myeloma.
Material and Method: A retrospective study in Mexican patients with multiple myeloma post-HSCT with lenalidomide maintenance for at least 12 months was done from February 2013 to December 2018. Epidemiologic, demographic, disease-related and treatment-related data were collected.
Results: Ten patients with multiple myeloma post-HSCT were included, with a biochemical and clinical progression free-survival at 24 months of 80% and 100%, respectively. No deaths were reported during the follow-up time. Half of the patients had adverse events related to the use of lenalidomide, all of them were grade I, most of them hematologic.
Conclusions: This study favors the use of lenalidomide maintenance in Mexican patients with multiple myeloma post-autologous HSCT, obtaining similar response rates as those reported elsewhere. This establishes the basis of second-generation immunomodulatory drugs as maintenance therapy post-autologous HSCT in our country.


REFERENCES

  1. Anderson KC. The 39th David A. Karnofsky Lecture: benchto- bedside translation of targeted therapies in multiple myeloma. J Clin Oncol 2012; 30(4): 445-452. doi: 10.1200/ JCO.2011.37.8919

  2. Anderson KC. Progress and paradigms in multiple myeloma. Clin Cancer Res 2016; 22(22): 5419-5427. doi: 10.1158/1078-0432.CCR-16-0625

  3. Sonneveld P. Management of multiple myeloma in the relapsed/refractory patient. Hematology 2017; Dec 8: 508-17. doi: 10.1182/asheducation-2017.1.508

  4. Ron-Magaña AL, Fernandez-Vargas OE, Barrera-Chairez E, et al. BEAM-modified conditioning therapy with cisplatin+dexamethasone instead of carmustine prior to autologous hematopoietic stem cell transplantation (HSCT) in patients with Hodgkin and non-Hodgkin lymphoma. Ann Transplant 2019; 24: 584-87. doi: 10.12659/AOT.918259

  5. Bazarbachi AH, Al-Hamed R, Malard F, et al. Relapsed refractory multiple myeloma: a comprehensive overview. Leukemia 2019; 33: 2343-57. doi: 10.1038/s41375-019- 0561-2

  6. Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 2014; 28(5): 1122-1128. doi: 10.1038/leu.2013.313

  7. Cavo M, Hájek R, Pantani L, et al. Autologous stem cell transplantation versus bortezomib-melphalan-prednisone for newly diagnosed multiple myeloma: second interim analysis of the phase 3 EMN02/HO95 study. Blood 2017; 130(suppl 1): 397. https://doi.org/10.1182/blood.V130. Suppl_1.397.397

  8. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348(19): 1875-1883. doi: 10.1056/NEJMoa022340

  9. Gambella M, Omedé P, Spada S, et al. Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis. Cancer 2019; 125(5): 750-760. doi: 10.1002/cncr.31854

  10. Munshi NC, Anderson KC. Minimal residual disease in multiple myeloma. J Clin Oncol. 2013; 31(20): 2523-2526. doi: 10.1200/JCO.2013.49.2124

  11. Holstein SA, Suman VJ, McCarthy PL. Update on the role of lenalidomide in patients with multiple myeloma. Ther Adv Hematol 2018; 9(7): 175-190. doi: 10.1177/2040620718775629

  12. Gay F, Engelhardt M, Terpos E, et al. From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives. Haematologica 2018; 103(2): 197-211. doi: 10.3324/ haematol.2017.174573

  13. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med 1996; 335(2): 91-97. doi: 10.1056/NEJM199607113350204

  14. Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med 2017; 376(14): 1311-1320. DOI: 10.1056/NEJMoa1611750

  15. Gay F, Oliva S, Petrucci MT, et al. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. Lancet Oncol 2015; 16(16): 1617-1629. doi: 10.1016/S1470-2045(15)00389-7

  16. Palumbo A, Cavallo F, Gay F, et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med 2014; 371(10): 895-905. DOI: 10.1056/ NEJMoa1402888

  17. McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012; 366(19): 1770-1781. DOI: 10.1056/ NEJMoa1114083

  18. Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 2012; 366(19): 1782-1791. DOI: 10.1056/NEJMoa1114138

  19. Jackson GH, Davies FE, Pawlyn C, et al. Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2019; 20(1): 57-73. doi: 10.1016/S1470-2045(18)30687-9

  20. McCarthy PL, Holstein SA, Petrucci MT, et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol 2017; 35(29): 3279-3289. doi: 10.1200/ JCO.2017.72.6679

  21. Jagannath S, Abonour R, Durie BGM, et al. Impact of post- ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM. Blood Adv 2018; 2(13): 1608-1615. doi: 10.1182/bloodadvances. 2018017186

  22. Takamatsu H, Munemoto S, Murata R et al. Post-transplantation consolidation and maintenance therapy with lenalidomide for Japanese patients with multiple myeloma. Anticancer Research 2013; 33: 5681-86.

  23. O’Donnell PH, Dolan ME. Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy. Clin Cancer Res 2009; 15(15): 4806-4814. doi: 10.1158/1078-0432.CCR-09-0344

  24. Phan VH, Tan C, Rittau A, Xu H, McLachlan AJ, Clarke SJ. An update on ethnic differences in drug metabolism and toxicity from anti-cancer drugs. Expert Opin Drug Metab Toxicol 2011; 7(11): 1395-1410. doi: 10.1517/17425255.2011.624513

  25. Ramamoorthy A, Pacanowski MA, Bull J, Zhang L. Racial/ ethnic differences in drug disposition and response: review of recently approved drugs. Clin Pharmacol Ther 2015; 97(3): 263-273. doi: 10.1002/cpt.61

  26. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20(9): 1467-1473. doi: 10.1038/sj.leu.2404284

  27. US Department of Health and Human Services, National Institutes of Health, & National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0. May 28, 2009. https://www.eortc.be/services/doc/ ctc/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf

  28. Kumar S, Paiva B, Anderson KC et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 2016; 17: e328-46. https://doi.org/10.1016/ S1470-2045(16)30206-6

  29. Yasuda SU, Zhang L, Huang SM. The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies. Clin Pharmacol Ther 2008; 84(3): 417-423. doi: 10.1038/clpt.2008.141

  30. Kumar SK, Therneau TM, Gertz MA, et al. Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc 2004; 79(7): 867-874. doi: 10.4065/79.7.867

  31. Al-Ani F, Louzada M. Post-transplant consolidation plus lenalidomide maintenance vs lenalidomide maintenance alone in multiple myeloma: A systematic review. Eur J Haematol 2017; 99: 479-88. doi: 10.1111/ejh.12961

  32. Gertz MA, Kumar S, Lacy MQ et al. Stem cell transplantation in multiple myeloma: impact of response failure with thalidomide or lenalidomide induction. Blood 2010; 115(12): 2348-53. doi: 10.1182/blood-2009-07-235531

  33. Tietsche de Moraes-Hungria V, Martínez-Baños DM, Peñafiel CR, et al. Multiple myeloma treatment patterns and clinical outcomes in the Latin America Haemato-Oncology (HOLA) Observational Study, 2008-2016. Br J Haematol 2020; 188: 383-93. doi: 10.1111/bjh.16124




2020     |     www.medigraphic.com